Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 7.90%4.08B | 5.92%4.19B | 7.76%3.9B | 8.00%14.91B | 0.73%3.56B | 9.80%3.78B | 5.23%3.95B | 17.75%3.62B | -11.98%13.8B | -9.59%3.53B |
| Cost of revenue | 4.95%12.08B | -10.09%11.51B | ||||||||
| Gross profit | 23.33%2.83B | -20.37%2.29B | ||||||||
| Operating expense | -1.40%3.34B | 8.08%3.6B | 9.09%3.4B | 47.71%930.68M | 1.00%3.17B | 11.41%3.39B | 0.15%3.34B | 18.28%3.12B | -27.75%630.06M | 133.97%3.14B |
| Selling and administrative expenses | ---- | ---- | ---- | 20.76%725.93M | ---- | ---- | ---- | ---- | -28.16%601.15M | ---- |
| -Selling and marketing expense | ---- | ---- | ---- | 24.47%391.71M | ---- | ---- | ---- | ---- | -40.19%314.7M | ---- |
| -General and administrative expense | ---- | ---- | ---- | 16.68%334.22M | ---- | ---- | ---- | ---- | -7.78%286.45M | ---- |
| Other operating expenses | -0.59%3.37B | 8.08%3.6B | 9.35%3.41B | 292.93%369.13M | 1.00%3.17B | 11.41%3.39B | 0.15%3.34B | 18.28%3.12B | -6.25%93.94M | 131.34%3.14B |
| Total other operating income | --27.67M | ---- | --8.35M | 152.79%164.39M | ---- | ---- | ---- | ---- | 0.13%65.03M | ---- |
| Operating profit | 89.31%733.72M | -5.70%584.4M | -0.53%497.91M | 14.10%1.9B | -1.38%389.13M | -2.48%387.57M | 44.78%619.71M | 14.51%500.58M | -17.18%1.66B | 12.38%394.58M |
| Net non-operating interest income (expenses) | 2.18%-31.9M | 20.16%-30.53M | 18.08%-38.18M | 29.23%-154.75M | 28.46%-37.55M | 43.16%-32.61M | 24.37%-38.24M | 20.01%-46.61M | 5.77%-218.68M | 15.01%-52.48M |
| Non-operating interest income | ---- | ---- | ---- | 180.03%57.75M | ---- | ---- | ---- | ---- | 201.17%20.62M | ---- |
| Non-operating interest expense | -2.18%31.9M | -20.16%30.53M | -18.08%38.18M | -10.14%195.62M | -28.46%37.55M | -43.16%32.61M | -24.37%38.24M | --46.61M | 3.25%217.68M | 29.54%52.48M |
| Total other finance cost | ---- | ---- | ---- | -21.89%16.88M | ---- | ---- | ---- | ---- | -23.04%21.62M | ---- |
| Net investment income | ||||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | -47.11%89.37M | -16.68%93.6M | 95.06%169.65M | 169.72%559.28M | 100.21%190.89M | 139.86%168.98M | 222.83%112.34M | 525.43%86.97M | 18.89%207.36M | 148.72%95.34M |
| Special income (charges) | 93.45%-485K | -2,613.19%-7.41M | ||||||||
| Less:Write off | ---- | ---- | ---- | -93.45%485K | ---- | ---- | ---- | ---- | 2,613.19%7.41M | ---- |
| Other non-operating income (expenses) | ||||||||||
| Income before tax | 51.01%791.2M | -6.68%647.47M | 16.35%629.38M | 39.95%2.3B | 24.01%542.47M | 27.64%523.95M | 68.29%693.81M | 37.71%540.94M | -15.68%1.65B | 33.60%437.44M |
| Income tax | 116.31%104.35M | 56.82%70.86M | 80.75%81.95M | 39.75%178.68M | 13.05%42.06M | 63.11%48.24M | 46.81%45.19M | 21.09%45.34M | -31.00%127.86M | 4,761.90%37.2M |
| Net income | 44.39%686.84M | -11.10%576.61M | 10.46%547.43M | 39.97%2.12B | 25.03%500.42M | 24.89%475.7M | 70.03%648.63M | 39.47%495.61M | -14.07%1.52B | 21.94%400.24M |
| Net income continuous operations | 44.39%686.84M | -11.10%576.61M | 10.46%547.43M | 39.97%2.12B | 25.03%500.42M | 24.89%475.7M | 70.03%648.63M | 39.47%495.61M | -14.07%1.52B | 21.94%400.24M |
| Noncontrolling interests | 68.31%123.55M | -34.85%93.03M | -2.17%85.66M | 18.59%359.01M | -30.06%55.14M | -1.86%73.4M | 88.64%142.8M | 19.32%87.57M | -15.86%302.72M | 16.89%78.84M |
| Net income attributable to the company | 40.02%563.3M | -4.40%483.58M | 13.17%461.77M | 45.29%1.77B | 38.55%445.27M | 31.42%402.3M | 65.42%505.83M | 44.71%408.04M | -13.61%1.22B | 23.24%321.39M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 40.02%563.3M | -4.40%483.58M | 13.17%461.77M | 45.29%1.77B | 38.55%445.27M | 31.42%402.3M | 65.42%505.83M | 44.71%408.04M | -13.61%1.22B | 23.24%321.39M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 40.16%0.0684 | -4.40%0.0587 | 13.13%0.056 | 45.29%0.2143 | 38.46%0.054 | 31.18%0.0488 | 64.61%0.0614 | 43.90%0.0495 | -14.04%0.1475 | 23.81%0.039 |
| Diluted earnings per share | 40.16%0.0684 | -4.40%0.0587 | 13.13%0.056 | 45.29%0.2143 | 38.46%0.054 | 31.18%0.0488 | 64.61%0.0614 | 43.90%0.0495 | -14.04%0.1475 | 23.81%0.039 |
| Dividend per share | 14.29%0.02 | 14.29%0.02 | 0.00%0.0175 | 0.00%0.07 | 0.00%0.0175 | 0.00%0.0175 | 0.00%0.0175 | 0.00%0.0175 | 16.67%0.07 | 0.00%0.0175 |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.